|Articles|November 16, 2020
- Pharmaceutical Executive-11-01-2020
- Volume 40
- Issue 11
Pharmaceutical Executive, November 2020 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive November 2020 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 5 years ago
Synthetic Biology and the Environmentover 5 years ago
Measuring Pharma’s Wider Mandateover 5 years ago
Patients as the North Starover 5 years ago
A Rare-Disease Must? Building Long-Term Relationshipsover 5 years ago
Making Remote Work a Success Beyond COVIDover 5 years ago
CRISPR for Diversity, and Humanity’s, Sakeover 5 years ago
Expediting the Cancer Treatment Pathover 5 years ago
Vaccine Authorization, Distribution Raise Multiple Challengesover 5 years ago
EU Leaders in High-Stakes Gamble on COVID ResponsesAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
FDA Makes Leadership Overhaul Following Commissioner Makary’s Departure: Report
2
Regeneron Enters $2.3 Billion Collaboration with Parabilis Medicines to Discover & Develop Multiple Therapeutic Candidates
3
The Risks and Benefits of FDA Reviewing Real-Time Data
4
FDA Approves Baxdrostat for Uncontrolled Hypertension in First-in-Class Entry
5